country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P10775A

Copy Link Print Information

BT1769 acetate

Kundenbewertung

Based on 1 Customer Validation

BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a K_d value of 3.35 nM against human targets. BT1769 acetate exhibits favorable pharmacokinetic properties. BT1769 acetate specifically binds to MT1-MMP via its bicyclic peptide component, delivering the cytotoxic agent MMAE (HY-15162) to antigen-expressing cells. It effectively inhibits tumor growth, induces complete responses, and significantly prolongs event-free survival in osteosarcoma patient-derived xenograft models. BT1769 acetate shows extremely low activity in Ewing sarcoma models and can be used in osteosarcoma-related research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₁₈₆H₂₆₉N₄₃O₅₀S·xC₂H₄O₂
Molecular Weight:3939.45 (free base)

Speicherung:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Kundenspezifische Peptidsynthese

BT1769 acetate Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle MMP Isoform-spezifische Produkte anzeigen :

In Vitro

BT1769 acetate (1.5625-100 nnM) binds to recombinant human MT1-MMP with a K_D of 3.35 nM and to recombinant mouse MT1-MMP with a K_D of 2.99 nM, showing high target affinity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BT1769 (acetate) (3.2 mg/kg; i.v.; once weekly) induces significant antitumor activity in HT1080 osteosarcoma xenografts in female BALB/c nude mice^[2].
BT1769 (acetate) (3 mg/kg; i.v.; once weekly; 4 weeks) significantly prolongs event-free survival and induces maintained complete responses in most tested osteosarcoma patient-derived xenograft models in female CB17SC scid^-/- mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CB17SC scid^-/- Mice (female, 5 to 8 weeks, subcutaneous flank xenografts with 6 distinct osteosarcoma patient-derived models: OS1, OS9, OS17, OS2, OS31, OS33)^[2]
Dosage:

3 mg/kg
Administration:

i.v.; once weekly; 4 consecutive weeks
Result:

Induced significantly prolonged event-free survival (EFS) in all 6 osteosarcoma models.
Achieved maintained complete responses (MCR) in 3 of the 6 models.
Had initial MCR followed by tumor recurrence at 9 weeks post-treatment in the OS17 model, correlating with a reduction in MT1-MMP expression.
Caused an average maximum weight loss of 6.8% across all models, indicating general tolerability.

Chemical Information

Appearance Solid
Molecular Weight 3939.45 (free base)
Formel C₁₈₆H₂₆₉N₄₃O₅₀S·xC₂H₄O₂
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 50 mg/mL (Need ultrasonic)

View the Complete Stock Solution Preparation Table

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Wang Y, et al. Abstract LB008: Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcomas (OS); Preclinical testing of BT1769, an MT1-MMP-targeted Bicycle Toxin Conjugate, in OS by the Pediatric Preclinical Testing Consortium (PPTC)[J]. Cancer Research, 2021, 81(13_Supplement): LB008-LB008.

[2]. Wang Y, et al. Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. Mol Cancer Ther. 2022;21(6):903-913. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BT1769 acetate

Alle MMP Isoform-spezifische Produkte anzeigen